Mark Heinen - 31 Mar 2022 Form 4 Insider Report for Better Therapeutics, Inc.

Role: Head of Finance and interim Chief Financial Officer
Signature: /s/ Mark Heinen
Issuer symbol: BTTX on OTC
Transactions as of: 31 Mar 2022
Net transactions value: +$9,900
Form type: 4
Filing time: 04 Apr 2022, 16:28:25 UTC
Previous filing: 15 Dec 2021
Next filing: 10 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTTX	Common Stock	Purchase	$9,900	+5,000	+50%	$1.98	15,000	31 Mar 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTTX	Stock Option (Right to Buy)	Award	$0	+32,800		$0.000000	32,800	01 Apr 2022	Common Stock	32,800	$1.97	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vests as to 1/4 of the shares subject to the stock option on April 1, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on April 1, 2022.

Remarks:

Head of Finance and interim Chief Financial Officer